Our primary focus is the development of therapies for extremely resistant forms of cancer. Our objective is to revolutionize a fundamental aspect of cancer therapy in order to offer chemotherapy that is both safer and more efficient. We possess three fundamental technologies, all stemming from discoveries originating at M.D. Anderson Cancer Center under the leadership of Dr. Waldemar Priebe and his research team. Among our drugs in the clinical stage are Annamycin, a cutting-edge Anthracycline variation under investigation for the treatment of relapsed or refractory acute myeloid leukemia (AML), and WP1066, an immunological/transcriptional modulator designed to combat brain tumors, pancreatic cancer, and AML.